Meyka Pro banner
Stereotaxis, Inc.

Stereotaxis, Inc. Fundamental Analysis (AMEX: STXS)

STXSAMEX
HealthcareMedical - Equipment & Services
$1.42
$0.02(1.39%)
U.S. Market opens in 62h 11m

Stereotaxis, Inc. Fundamental Analysis (AMEX: STXS)

Stereotaxis, Inc. (AMEX: STXS) shows moderate financial fundamentals with a PE ratio of -5.83, profit margin of -74.24%, and ROE of -1.33%. The company generates $0.0B in annual revenue with strong year-over-year growth of 20.28%.

Key Strengths

PEG Ratio-0.56

Areas of Concern

ROE-1.33%
Operating Margin-73.02%
We analyze STXS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -144.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-144.4/100

We analyze STXS's fundamental strength across five key dimensions:

Efficiency Score

Weak

STXS struggles to generate sufficient returns from assets.

ROA > 10%
-40.16%

Valuation Score

Excellent

STXS trades at attractive valuation levels.

PE < 25
-5.83
PEG Ratio < 2
-0.56

Growth Score

Excellent

STXS delivers strong and consistent growth momentum.

Revenue Growth > 5%
20.28%
EPS Growth > 10%
16.67%

Financial Health Score

Excellent

STXS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.30
Current Ratio > 1
1.42

Profitability Score

Weak

STXS struggles to sustain strong margins.

ROE > 15%
-132.62%
Net Margin ≥ 15%
-74.24%
Positive Free Cash Flow
No

Key Financial Metrics

Is STXS Expensive or Cheap?

P/E Ratio

STXS trades at -5.83 times earnings. This suggests potential undervaluation.

-5.83

PEG Ratio

When adjusting for growth, STXS's PEG of -0.56 indicates potential undervaluation.

-0.56

Price to Book

The market values Stereotaxis, Inc. at 8.24 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

8.24

EV/EBITDA

Enterprise value stands at -6.92 times EBITDA. This is generally considered low.

-6.92

How Well Does STXS Make Money?

Net Profit Margin

For every $100 in sales, Stereotaxis, Inc. keeps $-74.24 as profit after all expenses.

-74.24%

Operating Margin

Core operations generate -73.02 in profit for every $100 in revenue, before interest and taxes.

-73.02%

ROE

Management delivers $-1.33 in profit for every $100 of shareholder equity.

-1.33%

ROA

Stereotaxis, Inc. generates $-40.16 in profit for every $100 in assets, demonstrating efficient asset deployment.

-40.16%

Following the Money - Real Cash Generation

Operating Cash Flow

Stereotaxis, Inc. generates limited operating cash flow of $-14.97M, signaling weaker underlying cash strength.

$-14.97M

Free Cash Flow

Stereotaxis, Inc. generates weak or negative free cash flow of $-15.18M, restricting financial flexibility.

$-15.18M

FCF Per Share

Each share generates $-0.15 in free cash annually.

$-0.15

FCF Yield

STXS converts -11.03% of its market value into free cash.

-11.03%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.83

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.56

vs 25 benchmark

P/B Ratio

Price to book value ratio

8.24

vs 25 benchmark

P/S Ratio

Price to sales ratio

4.69

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.30

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.42

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.33

vs 25 benchmark

ROA

Return on assets percentage

-0.40

vs 25 benchmark

ROCE

Return on capital employed

-0.76

vs 25 benchmark

How STXS Stacks Against Its Sector Peers

MetricSTXS ValueSector AveragePerformance
P/E Ratio-5.8330.97 Better (Cheaper)
ROE-132.62%515.00% Weak
Net Margin-74.24%30203.00% Weak
Debt/Equity0.300.53 Strong (Low Leverage)
Current Ratio1.425.71 Neutral
ROA-40.16%-15.00% (disorted) Weak

STXS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Stereotaxis, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-2.76%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-160.44%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-211.67%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ